Fisetin-loaded nanostructured lipid carriers

Fisetin-loaded nanostructured lipid carriers has been studied in 1 paper since 2023: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 31, 2023: “Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma”.

Intervention

1 paper studies it4 findingsUpdated

See all 1 papers on fisetin-loaded nanostructured lipid carriers

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Cells and mice: a single group. Worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: Anusandhan National Research Foundation and 1 more
  • Animals1

What did studies of fisetin-loaded nanostructured lipid carriers find?

4

Studies of fisetin-loaded nanostructured lipid carriers measured 4 outcomes, among them NFE2L2, BAX and melanoma-associated metastasis.

NFE2L2

upin cells1

1 study
  1. Fisetin-loaded nanostructured lipid carriers increase NFE2L2 in cells (NQO1 expression also increased).

    “Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot results show enhanced expression of Nrf2/NQO1 genes”

    CellsNQO1 expression also increasednanostructured lipid carriers (Fis-NLCs)

    Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma

    Molecular pharmaceutics

More on NFE2L2

BAX

upin cells1

1 study
  1. Fisetin-loaded nanostructured lipid carriers increase BAX in cells (compared with pure fisetin; p53 also increased) (~2-fold higher than pure Fis).

    “The protein levels of BAX and p53 were ∼2-fold higher compared with that of pure Fis.”

    Cellscompared with pure fisetin; p53 also increasednanostructured lipid carriers (Fis-NLCs)

    Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma

    Molecular pharmaceutics

More on BAX

Melanoma-associated metastasis

downin animals1

1 study
  1. Fisetin-loaded nanostructured lipid carriers decrease melanoma-associated metastasis (compared with pure fisetin) (5.9-fold (lungs) and 10.7-fold (liver) higher inhibition).

    “In-vivo studies demonstrated 5.9- and 10.7-fold higher inhibition in melanoma-associated metastasis in the lungs and liver, respectively.”

    Animalscompared with pure fisetinnanostructured lipid carriers (Fis-NLCs)lung and liver

    Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma

    Molecular pharmaceutics

More on Melanoma-associated metastasis

IC50 in melanoma cells

downin cells1

1 study
  1. Fisetin-loaded nanostructured lipid carriers decrease IC50 in melanoma cells in cells (compared with pure fisetin) (at least ~3.2 times lower than Fis).

    “Fis-NLCs depicted at least ∼3.2 times lower IC50 value and ∼1.8 times higher drug uptake at 48 h in A-375 and B16F10 cells compared to that of Fis.”

    Cellscompared with pure fisetinnanostructured lipid carriers (Fis-NLCs)48 h

    Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma

    Molecular pharmaceutics

Latest